The D 3 dopamine receptor has a restricted regional distribution in brain and is regulated by dopaminergic agents. Additionally, the D 3 gene is implicated in the pathogenesis of several neuropsychiatric disorders or in their response to pharmacological agents. Elucidating its transcription control mechanisms is therefore of interest in order to explain these biological features of the D 3 gene. In this study, the 5 H¯a nking region of the rat D 3 gene was characterized by isolating the 5 H end of its cDNA as well as 4.6 kb of genomic sequence. Analysis of this region revealed the presence of two new exons 196-bp and 120-bp long, separated by an 855-bp intron, located several kilobases upstream of the previously published coding exons. Thus, current evidence indicates that the rat D 3 gene is organized into eight exons. Transcription initiation site was determined by primer extension analysis and repeated rounds of 5 H RACE and was found to localize at a pyrimidine-rich consensus`initiator' sequence, similar to the rat D 2 gene. The D 3 promoter lacks TATA or CAAT boxes but unlike that of other dopamine receptor genes has only 52% GC content. Functional analysis of D 3 promoter deletion mutants fused to a reporter gene in TE671 cells, which endogenously express this gene, revealed strong transcriptional activity localized within 36 nucleotides upstream of transcription start site, and a potent silencer between bases 237 and 2537. The D 3 promoter is inactive in C6 and COS7 cells. We conclude that the D 3 gene, similar to the closely related D 2 gene, is transcribed from a tissue speci®c promoter which is under intense negative control.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.